Immunotherapy Trial Helps Lung Cancer Patients ...

Posted by

Label: Featured News

In December, MesotheliomaHelp reported that Roche's immunotherapy drug atezolizumab (now known as TECENTRIQ), saw positive results in two Phase II clinical trials for non-small cell lung cancer patients (NSCLC). Now, Roche reports, in a separate trial the drug helped some lung cancer patients "live significantly longer compared to chemotherapy." In a Sept. 1 press release from Roche, the company reports TECENTRIQ showed a "statistically significant and clinically meaningful improvement in overall survival" compared with docetax
Read Full Story

Want Specific topic updates?